摘要【目的】探讨达格列净治疗糖尿病肾病(DN)的临床疗效及其对患者β细胞功能、肾功能指标的影响。【方法】两院收治的100例DN患者,随机分为观察组和对照组,每组50例。两组均接受常规治疗,包括生活方式调整、低脂和低盐饮食、运动锻炼、注射胰岛素等,对照组另外口服厄贝沙坦和阿托伐他汀,观察组在对照组基础上给予达格列净治疗,两组均治疗3个月。比较两组临床疗效及血尿素氮(BUN)、尿蛋白定量(UTP)、血肌酐(Scr)水平;分别检测患者空腹C肽(FC-P)、餐后2 h C肽(2hC-P)水平,计算并比较两组患者β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR);比较两组不良反应发生情况。【结果】观察组治疗总有效率为84.00%(42/50),明显高于对照组的64.00%(32/50),且差异有统计学意义(P<0.05)。治疗前,两组各项指标水平比较,差异均无统计学意义(P>0.05);治疗后,两组UTP、BUN、Scr水平较治疗前降低(P<0.05),且观察组三项指标均低于对照组(P<0.05);治疗后,两组2hC-P、HOMA-β水平较治疗前提高,HOMA-IR降低(P<0.05);且观察组HOMA-β水平高于、HOMA-IR水平低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】达格列净治疗DN有利于提高临床疗效,改善β细胞功能和肾功能指标,且安全性较高,具有推广价值。
Abstract：【Objective】To explore the effect of daggligin on β-cell function and renal function indexes in patients with diabetic nephropathy (DN). 【Methods】A total of 100 DN patients admitted to two hospitals were randomly divided into the observation group and the control group,with 50 patients in each group. Both groups received routine treatment,including lifestyle adjustments,low-fat and low salt diet,exercise,and insulin injections. The control group received oral administration of irbesartan and atorvastatin,while the observation group received treatment with daggliflozin in addition to the treatment of the control group. Both groups were treated for 3 months. The clinical efficacy of two groups was compared,including blood urea nitrogen (BUN),urinary protein quantification (UTP),and serum creatinine (Scr) levels. Levels of fasting C-peptide (FC-P) and 2-hour postprandial C-peptide (2hC-P) in patients were measured; And β cell function index (HOMA-β)、 insulin resistance index (HOMA-IR) were calculated and compared in the two groups of patients.. The occurrence of adverse reactions between the two groups was analyzed as well. 【Results】The total effective rate of the observation group was 84.00% (42/50),which was significantly higher than that of the control group 64.00% (32/50),and the difference was statistically significant (P<0.05). Before treatment,there were no statistically significant differences in the levels of various indicators between the two groups (P>0.05). After treatment,the levels of UTP,BUN,and Scr in both groups decreased,if compared to before treatment (P<0.05); And all three indicators above in the observation group were lower than those in the control group (P<0.05). After treatment, the levels of 2hC-P and HOMA-β in the two groups got improved compared to those before treatment,while HOMA-IR decreased (P<0.05). The level of HOMA-β in the observation group was higher than that in the control group,while HOMA-IR level was lower than that in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The treatment of DN with daggliflozin is beneficial for improving clinical efficacy,β cell function and renal function indicators. It is a safe way,which has promotional value.
吴晓雪, 许荣, 田江坤. 达格列净治疗糖尿病肾病的临床疗效及其对患者β细胞功能、肾功能指标的影响[J]. 医学临床研究, 2023, 40(5): 673-675.
WU Xiao-xue, XU Rong, TIAN Jiang-kun. Effect of Daggligin on β-cell Function and Renal Function Indexes in Patients with Diabetic Nephropathy. JOURNAL OF CLINICAL RESEARCH, 2023, 40(5): 673-675.
[1] NOWAK N. Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy:From current human evidence to future possibilities[J].J Diabetes Investig,2020,11(5):1085-1096. [2] FERNANDES R,VIANA S D,NUNES S,et al. Diabetic gut microbiota dysbiosis as an inflammaging and immunosenescence condition that fosters progression of retinopathy and nephropathy[J].Biochim Biophys Acta Mol Basis Dis,2019,1865(7):1876-1897. [3] ROOINTAN A. Non-invasive metabolic biomarkers for early diagnosis of diabetic nephropathy:Meta-analysis of profiling metabolomics studies[J].Nutr Metab Cardiovasc Dis,2021,31(8):2253-2272. [4] 王华. 参麦地黄汤联合达格列净对气阴亏虚型早期糖尿病肾病患者血糖及尿微量白蛋白的影响-附49例临床资料[J].江苏中医药,2022,54(4):44-46. [5] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华内分泌代谢杂志,2014,30(10):893-942. [6] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志,2017,37(1):28-34. [7] ANDRASSY K M. Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'[J].Kidney Int,2013,84(3):622-623. [8] SHIKATA K. Randomized trial of an intensified,multifactorial intervention in patients with advanced-stage diabetic kidney disease:Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan)[J].J Diabetes Investig,2021,12(2):207-216. [9] 黎俏洁.达格列净与吡格列酮联合二甲双胍治疗2型糖尿病的疗效及对胰岛素敏感性和胰岛α和β细胞功能的影响[J].川北医学院学报,2022,37(1):95-98. [10] 邓丽萍,武红梅,袁唯唯.维格列汀二甲双胍复方制剂联合达格列净治疗新诊断2型糖尿病患者的疗效及安全性观察[J].中国糖尿病杂志,2022,30(2):116-119. [11] 吴金婵,冯光球,陈娟.达格列净对血糖控制不达标2型糖尿病病人胰岛β细胞功能及胰岛素抵抗的影响[J].中西医结合心脑血管病杂志,2021,19(21):3749-3751. [12] 黄妙玲,黄莹,郑晓斌.达格列净联合胰岛素泵强化治疗新发糖尿病的效果及对胰岛β细胞功能的影响[J].解放军预防医学杂志,2019,37(3):30-32. [13] 王绘,张琳琳,高玮,等.达格列净对初诊2型糖尿病患者胰岛β细胞功能及肠道菌群的影响[J].中华糖尿病杂志,2022,14(4):337-344. [14] 张志勇,李明旭,于海,等.达格列净治疗糖尿病肾病84例临床疗效观察[J].第二军医大学学报,2021,42(9):1062-1066.
2023, Vol. 40 
